46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223

  
15 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100048699
2021-05-252021-07-12A multicentre, randomized, parallel-controlled clinical study of the efficacy and safety of Iguratimod combination therapy with JAK inhibitor in the treatment of csDMARDs-IR active rheumatoid arthritisClinical cohort study of organ injury and repair in severe rheumatic diseases---rheumatoid arthritis Rheumatoid ArthritisA:Iguratimod combination therapy with JAK inhibitor;B:JAK inhibitor;Qilu Hospital of Shandong UniversityNULLRecruiting1865BothA:180;B:180;China
2NCT04928066
(ClinicalTrials.gov)
March 1, 20209/6/2021The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RAEfficacy and Safety of Tofacitinib (TF) Combined With Iguratimod(IGU) in the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)Arthritis, RheumatoidDrug: Iguratimod;Drug: Tofacitinib;Drug: PredQilu Hospital of Shandong UniversityNULLRecruiting18 Years80 YearsAll100Phase 4China
3ChiCTR1900021686
2019-03-152019-03-05A observational study for iguratimod combined with methotrexate in remission or reversion bone erosion of rheumatoid arthritisA observational study for iguratimod combined with methotrexate in remission or reversion bone erosion of rheumatoid arthritis Rheumatoid arthritisCase Series:IGU combined with MTX ;Nanjing Drum Tower HospitalNULLPending1870BothCase Series:30;Phase 4China
4ChiCTR1800015615
2018-05-012018-04-11Clinical observation of the protective effect of iguratimod on rheumatoid arthritisClinical observation of the protective effect of iguratimod on rheumatoid arthritis Rheumatoid Arthritisfirst:MTX;second:MTX in combination with Irammod;third:MTX and LEF;fourth:MTX, LEF and Irammod;Tianjin First Central HospitalNULLPending1875Bothfirst:30;second:30;third:30;fourth:30;China
5JPRN-UMIN000027719
2017/06/1212/06/2017Effect of tapering methotrexate in rheumatoid arthritis patients after add-on iguratimod therapy. rheumatoid arthritis/remissionadd-on iguratimod
tapering MTX
continuing the treatment
Osaka Medical CollegeNULLRecruiting20years-old100years-oldMale and Female100Not selectedJapan
6NCT03855007
(ClinicalTrials.gov)
January 1, 201715/2/2019The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months TreatmentProspective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in ChinaArthritis, RheumatoidDrug: Iguratimod;Drug: MTX;Drug: HCQ;Drug: PredQilu Hospital of Shandong UniversityNULLActive, not recruiting16 Years90 YearsAll200Phase 4China
7JPRN-UMIN000020833
2015/10/0901/02/2016The efficacy of Iguratimod, and adding Adalimumab in patients with active rheumatoid arthritis: an open label multicenter randomized parallel study. Rheumatoid arthritisAdminister MTX 6-16mg/week for 12 weeks to patients with MDA-RA.
If patients can't take MTX, administer IGU 25-50mg/day or Tac 1.5-3.0mg/day for 12 weeks.

Administer ADA 40mg/2weeks for 24weeks additionally, in case of MDA taking MTX or IGU, Tac for 12 weeks.
If patients maintain remission for 24weeks, discontinue ADA by their own will, after 48 weeks administering ADA.
Zenjinkai Shimin-no-mori HospitalNULLComplete: follow-up complete20years-oldNot applicableMale and Female240Not selectedJapan
8NCT02275299
(ClinicalTrials.gov)
September 201323/10/2014Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid ArthritisA Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisDrug: Iguratimod;Drug: Leflunomide;Drug: MethotrexateJiangsu Simcere Pharmaceutical Co., Ltd.NULLRecruiting18 Years70 YearsBoth240Phase 4China
9JPRN-JapicCTI-152782
12/9/201229/01/2015Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisInvestigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis Rheumatoid ArthritisIntervention name : Kolbet
INN of the intervention : Iguratimod
Dosage And administration of the intervention : Oral
Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)NULLBOTH2000NANULL
10JPRN-JapicCTI-132051
12/9/201223/01/2013Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisInvestigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis Rheumatoid ArthritisIntervention name : iguratimod (Careram)
Dosage And administration of the intervention : Oral
Eisai Co., Ltd.NULLBOTH2000NANULL
11NCT01850966
(ClinicalTrials.gov)
September 12, 20128/5/2013Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisInvestigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: IguratimodEisai Co., Ltd.NULLCompletedN/AN/AAll2747Japan
12NCT01893151
(ClinicalTrials.gov)
July 20122/7/2013Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRIA Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI)Rheumatoid ArthritisDrug: Iguratimod;Drug: Iguratimod placeboJiangsu Simcere Pharmaceutical Co., Ltd.NULLRecruiting18 Years65 YearsBoth200Phase 4China
13NCT01548001
(ClinicalTrials.gov)
May 20125/3/2012Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid ArthritisA Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: Iguratimod;Drug: MethotrexateJiangsu Simcere Pharmaceutical Co., Ltd.NULLActive, not recruiting18 Years65 YearsBoth910Phase 4China
14NCT01554917
(ClinicalTrials.gov)
May 201212/3/2012A Study of Iguratimod in Patients With Active Rheumatoid ArthritisA Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA)Rheumatoid ArthritisDrug: IguratimodJiangsu Simcere Pharmaceutical Co., Ltd.NULLCompleted18 YearsN/AAll1759Phase 4China
15ChiCTR-TRC-10000850
2008-10-012010-04-26Phase III clinical trial of Iguratimodin rheumatoid arthritisPhase III clinical trial of Iguratimodin rheumatoid arthritis rheumatoid arthritis3:Experimental group: Iguratimod tablet, nimesulide dummy tablet; positive control group: taking nimesulide and Iguratimod dummy tablet; placebo group: taking Iguratimod dummy tablet and nimesulide dummy tablet. ;Anhui Medical UniversityNULLCompleted1865Both3:600;3 (Phase 3 study)China